Better Life Through Better Science
KaloBios is developing a robust proprietary portfolio of customized, targeted, first-in-class monoclonal antibodies designed to significantly improve the care of seriously ill patients with difficult to treat diseases.
Recent Corporate Highlights
- Early completion of enrollment of 160 patients in a planned 150 patient KB003 Phase 2 severe asthma clinical trial
- Initiated 180 patient Phase 2 clinical trial for KB001-A in cystic fibrosis
- Sanofi granted Fast Track Status for KB001-A in Pa pneumonia prevention
- Received Orphan Drug designation from the United States Food and Drug Administration (FDA) for KB001-A for the treatment of Pa lung infection in CF patients